Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04248868 · ClinicalTrials.gov registry record · Phase 3
tPA by Endovascular Administration for the Treatment of Submassive PE Using CDT for the Reduction of Thrombus Burden
A Phase 3 study of Pulmonary Embolism, sponsored by Thrombolex.
- Completed
- Registry status
- Phase 3
- Development phase
- 109
- Enrollment target
- 19
- Study locations
NCT04248868 is a Phase 3 study of Pulmonary Embolism that has completed, run by Thrombolex. The registered enrollment target is 109 participants, below the 3,056-participant average among 48 other Pulmonary Embolism trials with a reported enrollment target (96% lower). The trial reports 19 study locations across 13 states.
The verdict
NCT04248868, a Phase 3 study of Pulmonary Embolism, has completed, sponsored by Thrombolex.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 109 participants
- Enrollment target
- 19
- Study locations
Study Summary
To demonstrate the efficacy and safety of the Bashir™ Endovascular Catheter for the administration of pharmaco-mechanical catheter directed therapy using low dose r-tPA for the treatment of acute submassive pulmonary embolism.
Conditions Studied
Interventions
- DRUG r-tPA
- DEVICE The Bashir™ Endovascular Catheter
Study Locations (19)
Pennsylvania
- UPMC Hamot - Erie
- Temple University Hospital - Philadelphia
- UPMC Heart and Vascular Institute - Pittsburgh
Florida
- Miami Cardiac & Vascular Institute - Miami
- Advent Health Orlando - Orlando
Georgia
- Emory - Atlanta
- Piedmont Heart Institute - Atlanta
Michigan
- Ascension St. John Hospital - Detroit
- Beaumont Hospital, Royal Oak - Royal Oak
New York
- St. Joseph's Hospital - Liverpool
- NYU Langone - New York
California
- UCLA - Los Angeles
Illinois
- Loyola University Chicago - Maywood
Indiana
- Ascension St. Vincent - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 109 participants |
| Start Date | 2020-06-23 |
| Est. Completion | 2022-06-23 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04248868
The ClinicalTrials.gov registry entry for NCT04248868 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 109 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,056-participant average among 48 other Pulmonary Embolism trials with a reported enrollment target (96% lower). The listed sponsor is Thrombolex, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pulmonary Embolism appearing as the primary indexed condition, and to 2 interventions - of which r-tPA is the first listed.
NCT04248868 reports 19 study locations spanning 13 distinct geographic areas - top geographies include Pennsylvania, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT04248868 about?
NCT04248868 is a clinical study titled "tPA by Endovascular Administration for the Treatment of Submassive PE Using CDT for the Reduction of Thrombus Burden". To demonstrate the efficacy and safety of the Bashir™ Endovascular Catheter for the administration of pharmaco-mechanical catheter directed therapy using low dose r-tPA for the treatment of acute submassive pulmonary embolism.
What is the current status of trial NCT04248868?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 109 participants. The study started on 2020-06-23. Estimated completion is 2022-06-23.
What conditions does trial NCT04248868 study?
This clinical trial studies the following conditions: Pulmonary Embolism.
What interventions are being tested in trial NCT04248868?
The interventions under investigation include: r-tPA (DRUG), The Bashir™ Endovascular Catheter (DEVICE).
Who is sponsoring clinical trial NCT04248868?
This trial is sponsored by Thrombolex, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04248868 being conducted?
This trial has 19 study locations across California, Florida, Georgia, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Embolism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pulmonary Embolism - Thrombus Removal With Catheter-Directed Therapy
RECRUITING · Phase 3
-
A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE
ACTIVE NOT RECRUITING · Phase 3
-
Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism
COMPLETED · Phase 3
-
A Study of Mobility Outcomes in Post-Pulmonary Embolic Disease
RECRUITING · NA
-
Intervention to Improve Utilization of Extended Venous Thromboembolism Prophylaxis After Cancer Surgery
RECRUITING · NA
-
Clinical Utility of Portable Dynamic Chest X Ray (DDR) in the ICU
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.